GDC-0941, a Novel Class I Selective PI3K Inhibitor, Enhances the Efficacy of Docetaxel in Human Breast Cancer Models by Increasing Cell Death In Vitro and In Vivo

Clinical Cancer Research, 06/12/2012

GDC–0941 augments the efficacy of docetaxel by increasing drug–induced apoptosis in breast cancer models.

Print Article Summary Cat 2 CME Report